Pharmaceutical News

RSS

Bachmann, Perry wrestle over HPV issue

During the last debate, Michele Bachmann and Rick Perry clashed over their positions on the HPV vaccine. During Thursday night's Orlando debate, the issue again emerged.

23 Sep 2011

Momenta, Sandoz file patent suit against Amphastar and Watson over Enoxaparin Sodium Injection

Watson Pharmaceuticals, Inc. today confirmed that Momenta Pharmaceuticals, Inc. and Sandoz Inc. have filed suit against Amphastar Pharmaceuticals, Inc. and Watson on September 21, 2011 in the United States District Court for the District of Massachusetts.

23 Sep 2011

Study identifies genetic mutations that affect immune response to measles vaccination

Researchers at Mayo Clinic are hacking the genetic code that controls the human response to disease vaccination, and they are using this new cipher to answer many of the deep-seated questions that plague vaccinology, including why patients respond so differently to identical vaccines and how to minimize the side effects to vaccination.

23 Sep 2011

IU professor to study factors influencing young women's adoption of HPV vaccine

Dena S. Cox, a professor of marketing and faculty fellow at the Kelley School of Business Indianapolis, has received a $99,600, two-year research grant from Merck to study factors influencing young women's adoption of the human papillomavirus (HPV) vaccine.

23 Sep 2011

CoPlex, Hawthorn sign license agreement for hawAD14 Alzheimer's drug

CoPlex Therapeutics has signed an exclusive global license agreement with Hawthorn Pharmaceuticals to develop and commercialize hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer's and other neurodegenerative diseases.

23 Sep 2011

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-200 was recently granted patents in Singapore and South Africa. These patents significantly strengthen the Adamis APC-200 patent portfolio for the use of APC-200 in the treatment of early and late stage prostate cancer.

23 Sep 2011

Shire announces update on approval status and availability of ProAmatine SOH drug

Shire plc, the global specialty biopharmaceutical company, announces an update on the approval status and availability of ProAmatine (midodrine HCl), a medicine approved for the treatment of symptomatic orthostatic hypotension.

23 Sep 2011

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

23 Sep 2011

Study: Opioid drugs can increase risk of pneumonia in older adults

Opioids -- a class of medicines commonly given for pain -- were associated with a higher risk of pneumonia in a study of 3,061 adults, aged 65 to 94, e-published in advance of publication in the Journal of the American Geriatrics Society.

23 Sep 2011

USPTO issues patent for Lixte's LB-100 to treat cancer

John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announces that the United States Patent and Trademark Office awarded a patent on its lead compound, LB-100, as well as a number of structurally related compounds, which has shown promising anti-cancer activity.

23 Sep 2011

Anti-obesity drug Contrave may get another chance to prove itself

With rise obesity around the world there should have been a number of drugs to combat it. The reality is different. There are no safe and effective drugs in the market at present.

22 Sep 2011

Jefferson experts review most commonly used CAM practices for mood disorders

Mood disorders are among the most prevalent mental health issues today. While medication is available, more and more people are turning to complementary and alternative medicine (CAM), including herbal remedies, acupuncture, and meditation to help manage their mood disorders.

22 Sep 2011

New portable test can quickly and economically detect adulterated heparin

Scientists are reporting refinement of a new test that promises to help assure the safety of supplies of heparin, the blood thinner taken by millions of people worldwide each year to prevent blood clots.

22 Sep 2011

Early ART cost effectiveness in resource-poor settings

A study published in PLoS Medicine shows "that the new WHO guidelines for early [antiretroviral treatment (ART)] initiation can be cost-effective in resource-poor settings, information that should help policymakers in developing countries allocate their often limited resources," according to a PLoS press release.

22 Sep 2011

Humour therapy as effective as antipsychotic drugs in managing agitation in dementia patients

Humour therapy is as effective as widely used antipsychotic drugs in managing agitation in patients with dementia - and avoids serious drug side effects, a new study shows.

22 Sep 2011

Cannabinoids may block development of PTSD symptoms after traumatic experience

Cannabinoids (marijuana) administration after experiencing a traumatic event blocks the development of post-traumatic stress disorder (PTSD)-like symptoms in rats, according to a new study conducted at the University of Haifa and published in the journal Neuropsychopharmacology.

22 Sep 2011

Methylphenidate drug may induce arousal from general anesthesia

Administration of the commonly used stimulant drug methylphenidate (Ritalin) was able to speed recovery from general anesthesia in an animal study conducted at Massachusetts General Hospital.

22 Sep 2011

Early ART can be cost-effective and decrease mortality in HIV patients

Researchers at Weill Cornell Medical College and GHESKIO have shown that early treatment of HIV not only saves lives but is also cost-effective. Results are published in today's edition of PLoS Medicine.

22 Sep 2011

Digna Biotech receives FDA Orphan Drug status for cardiotrophin-1 to treat ALF

Digna Biotech, a Spanish biotechnological company, announces that the Food and Drug Administration (FDA) granted cardiotrophin-1 (CT-1) Orphan Drug status for use in the treatment of acute liver failure.

22 Sep 2011

Ariel Pharmaceuticals in-licenses AP-1531 from BTG for acute migraine attacks

Ariel Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on the development and commercialization of products for acute central nervous system (CNS) diseases and trauma, announced today that it has in-licensed its lead product, AP-1531, for the treatment of acute migraine attacks, from the specialist healthcare company BTG International Ltd.

22 Sep 2011